Polymorphisms of glutathione S-transferase genes and survival of resected hepatocellular carcinoma patients

Table 5 Cumulative effects of unfavorable genotypes on overall survival of hepatocellular carcinoma patients

Group (number of unfavorable genotypes1)	Death/Total	HR (95%CI)	P value
In all patients
Group 1 (0)	44/95	1 (ref)
Group 2 (1)	47/97	1.08 (0.71-1.63)	0.730
Group 3 (2)	20/22	1.70a (1.30-2.22)	< 0.001a
P for trend			0.004a
In patients with age ≤ 55
Group 1 (0)	18/47	1 (ref)
Group 2 (1)	26/45	1.01 (0.52-1.95)	0.975
Group 3 (2)	14/16	2.00a (1.40-3.86)	< 0.001a
P for trend			0.003a
In patients with male gender
Group 1 (0)	36/82	1 (ref)
Group 2 (1)	34/75	0.97 (0.60-1.56)	0.898
Group 3 (2)	18/19	1.94a (1.45-2.59)	< 0.001a
P for trend			0.002a
In patients with cirrhosis
Group 1 (0)	20/56	1 (ref)
Group 2 (1)	24/56	1.29 (0.71-2.35)	0.410
Group 3 (2)	14/14	1.97a (1.39-2.79)	< 0.001a
P for trend			0.001a

¹Unfavorable genotypes: GSTO2: rs7085725 (WV or VV) and GSTP1: rs4147581 (WW).

^aP < 0.05 was considered statistically significant. WW: Homozygous wild-type genotype; WV: heterozygous genotype; VV: Homozygous variant genotype.